Novartis AG
NVS
$125.50
$0.490.39%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.86% | 12.02% | 11.30% | 10.73% | 8.96% |
| Total Other Revenue | 49.52% | 46.35% | 18.94% | 15.16% | 7.64% |
| Total Revenue | 12.88% | 12.95% | 11.50% | 10.85% | 8.92% |
| Cost of Revenue | 10.93% | 9.49% | 6.76% | 6.63% | -1.09% |
| Gross Profit | 13.50% | 14.07% | 13.11% | 12.31% | 12.55% |
| SG&A Expenses | 6.59% | 5.59% | 2.77% | 0.62% | 2.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -64.95% | 132.36% | 355.63% | 264.51% | 354.10% |
| Total Operating Expenses | 13.91% | 10.22% | 8.96% | 8.01% | -4.22% |
| Operating Income | 10.90% | 19.05% | 17.61% | 18.42% | 48.03% |
| Income Before Tax | 28.96% | 43.21% | 53.29% | 49.51% | 53.12% |
| Income Tax Expenses | 108.82% | 142.01% | 230.87% | 208.71% | -8.54% |
| Earnings from Continuing Operations | 22.34% | 35.23% | 41.16% | 39.28% | 62.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 888.49% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 150.00% | 900.00% | 66.67% | 150.00% | 200.00% |
| Net Income | -18.24% | -15.59% | -15.65% | -19.59% | 124.64% |
| EBIT | 10.90% | 19.05% | 17.61% | 18.42% | 48.03% |
| EBITDA | 4.67% | 9.00% | 6.33% | 4.79% | 29.67% |
| EPS Basic | -14.70% | -12.56% | -13.28% | -17.72% | 130.92% |
| Normalized Basic EPS | 14.92% | 23.31% | 21.47% | 20.36% | 54.87% |
| EPS Diluted | -14.76% | -12.68% | -13.39% | -17.71% | 130.18% |
| Normalized Diluted EPS | 14.92% | 23.29% | 21.43% | 20.28% | 54.96% |
| Average Basic Shares Outstanding | -3.81% | -3.35% | -2.90% | -2.76% | -3.01% |
| Average Diluted Shares Outstanding | -3.80% | -3.30% | -2.83% | -2.66% | -3.01% |
| Dividend Per Share | -1.44% | -1.44% | -1.44% | -1.44% | 13.24% |
| Payout Ratio | 0.25% | 0.21% | 0.76% | 0.31% | -0.53% |